menu
search
Skip to main content
search

Global pharmaceutical company

Delivers innovative health solutions to prevent and treat diseases.

1455924911

What is it?

A global biopharmaceutical company focused on developing important medicines and vaccines aimed at advancing the prevention and treatment of serious diseases.

Competitive advantage

The issuer has a strong commitment to research and development, which fuels continuous innovation. As a result, the company benefits from a well-diversified product range, with the company not reliant on a single drug. Furthermore, the depth of the issuer’s late-stage drugs in its development pipeline is, in our view, stronger than its peers. This pipeline of innovative therapies may not only improve patient outcomes but also drive revenue growth. The issuer also benefits from a strong brand reputation, built over decades of delivering life-changing drugs, which translates into a sticky buyer base and stable sales. We believe these competitive advantages act as catalysts for stronger fundamentals, which may be supportive of the credit over time.

What factors led to a buy decision

Our security selection decisions are driven by a rigorous, bottom-up assessment of company valuations and fundamentals, as well as a thorough understanding of ESG and climate risks.1 We identified this issuer as being attractively valued, relative to our understanding of the business fundamentals, as we believe the issuer has a demonstrably strong balance sheet with meaningful upside potential from their reinvigorated drug pipeline. In our view, the credit spreads, like the equity price, had failed to recognise the issuer’s revenue and cash flow potential, especially relative to lower-quality peers. Furthermore, we felt that the issuer’s environmental and sustainability strategy was under-appreciated by the market. For example, we took a favourable view on the company’s governance, as the new CEO redefined the company’s strategy and culture. The issuer has also demonstrated a strong understanding and management of climate risks, which included a strategy to reduce their carbon emissions. Collectively, the issuer’s environmental and sustainability strategy could be supportive of the credit as these factors become recognised by the market.

Key points

  • Diversified product range with a deep late-stage drug development pipeline.
  • Robust fundamentals and, in our view, attractively valued with meaningful upside potential.
  • Strong understanding and management of climate risks.